A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Bayer

Status: Completed

Conditions: Lymphoma, Follicular; Non-Hodgkin Lymphoma

Treatments: Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Study type: Observational

Funder types: Industry

Identifiers

NCT01164696

ZV0710BE

13455

Details and patient eligibility

About

The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced cancer of the lymph nodes of follicular type at study inclusion
• The patient has relapsed or has refractory disease, after previous treatment with rituximab
• Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
• The patient is >= 18 years of age
• Patient has given informed consent

Exclusion criteria

• Patient is unwilling or unable to give informed consent
• Patient is participating in another clinical trial

Trial design

30 participants in 1 patient group

Group 1

Treatment:

Drug: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)